Breaking News Instant updates and real-time market news.

PFE

Pfizer

$42.67

-0.39 (-0.91%)

08:15
06/12/19
06/12
08:15
06/12/19
08:15

Pfizer announces results from ORAL Shift study

Pfizer announced results from ORAL Shift, a Phase 3b/4 study in adult patients with moderately to severely active rheumatoid arthritis, or RA. Patients who achieved low disease activity, or LDA with Xeljanz extended release, or XR, 11 mg once daily, or QD, plus methotrexate, or MTX, after a 24-week open-label run-in period, were randomized to evaluate the efficacy and safety of Xeljanz XR 11 mg QD as monotherapy after MTX withdrawal compared with Xeljanz XR with continued MTX. The study demonstrated non-inferiority of MTX withdrawal with Xeljanz XR 11 mg QD compared to Xeljanz XR 11 mg QD plus MTX at week 48 as measured by the primary endpoint, the change in the Disease Activity Score from randomization at week 24 to the end of the double-blind MTX withdrawal phase at week 48. The study results will be presented during a late-breaking oral session at the European Congress of Rheumatology, or EULAR. For the primary efficacy analysis, patients who achieved Clinical Disease Activity Index low disease activity at week 24 were randomized into the MTX withdrawal phase resulting in least squares mean changes in DAS28-4 from weeks 24 to 48 of 0.33 and 0.03 in the Xeljanz XR monotherapy and Xeljanz XR plus MTX groups, respectively. The primary analysis showed that Xeljanz XR 11 mg QD monotherapy was non-inferior to Xeljanz XR 11 mg QD with MTX at week 48. The safety findings in ORAL Shift include the most frequently reported adverse events, or AEs, for each study group in the double-blind treatment period of nasopharyngitis, upper respiratory tract infection and bronchitis. Rates of AEs, serious AEs, or SAEs, and discontinuations due to AEs were generally comparable between treatment arms. In the Xeljanz XR monotherapy group, there were 10 SAEs and 5 discontinuations due to AEs. In the Xeljanz XR plus MTX group, there were 5 SAEs and 5 discontinuations due to AEs. During the double-blind withdrawal phase of the study, AEs were reported in 40.5% of patients in the Xeljanz XR monotherapy treatment group and 41.0% of patients in the Xeljanz XR plus MTX treatment group. In addition, SAEs were reported in 3.8% of patients in the Xeljanz XR monotherapy treatment group and 1.9% of patients in the Xeljanz XR plus MTX treatment group. In the double-blind treatment period, there were two deaths reported in the Xeljanz XR plus MTX treatment group.

  • 12

    Jun

  • 13

    Jun

  • 28

    Aug

PFE Pfizer
$42.67

-0.39 (-0.91%)

05/29/19
CANT
05/29/19
NO CHANGE
Target $53
CANT
Overweight
Pfizer sales potential Vyndaqel/Vyndamax underappreciated, says Cantor
Cantor Fitzgerald analyst Louise Chen says her "quick poll" of cardiologists supports the view that the peak sales potential of Pfizer's Vyndaqel/Vyndamax is underappreciated. The sales could be "meaningfully higher" than the 2024 consensus forecasts of $1.5B given a treatment cost of $225,000 per patient per year and a potential treatment population of 1M-plus in the U.S., Chen tells investors in a research note. She thinks the growing usage of scintigraphy for diagnosing transthyretin amyloid cardiomyopathy will increase the number of patients that are identified and eligible for treatment. The analyst reiterates an Overweight rating on Pfizer with a $53 price target.
05/30/19
GUGG
05/30/19
NO CHANGE
GUGG
Buy
Array BioPharma could be seen as target after 'de-risking' data, says Guggenheim
Guggenheim analyst Michael Schmidt said Array Biopharma (ARRY) may be perceived by investors as a theoretical acquisition target following the disclosure of Phase 3 interim results of Braftovi/Mektovi in BRAF+ colorectal cancer, which he views as positive and a "de-risking event." 67% of announced acquisitions in oncology with a comparable market cap to Array had what he would consider major pipeline de-risking events in the 6 months prior to their deal announcements, Schmidt tells investors. Merck (MRK) and Pfizer (PFE) "seem to have most bandwidth for a deal," said Schmidt, who added that those two along with Bristol-Myers (BMY), AstraZeneca (AZN) and Roche (RHHBY) scored highest as possible large cap theoretical acquirers of Array in his analysis. Schmidt raised his price target on Array Biopharma shares to $38 from $37, though his analysis suggests a potential $40-$50 acquisition price if the company were to be bought.
06/04/19
MSCO
06/04/19
INITIATION
Target $48
MSCO
Overweight
Pfizer resumed with an Overweight at Morgan Stanley
Morgan Stanley analyst David Risinger resumed coverage of Pfizer with an Overweight rating and $48 price target, stating that he sees Ibrance and pipeline products driving accelerating growth starting next year. Risinger estimates Pfizer will see 3-yr revenue CAGR of 6% from FY20-23 and EPS growth of 11% over the same period, he tells investors.
06/04/19
06/04/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Uber (UBER) was initiated with an Overweight at Barclays and Morgan Stanley, an Outperform at Oppenheimer, Cowen, William Blair, and JMP Securities, a Buy at Canaccord, SunTrust, Deutsche Bank, Loop Capital, Mizuho, BTIG, Needham, and BofA/Merrill, and a Neutral at Citi. 2. Lyft (LYFT) was initiated with a Buy at BTIG, SunTrust, and Citi, a Hold at Loop Capital, and an Equal Weight at Barclays. 3. Alibaba (BABA), JD.com (JD), and Twitter (TWTR) were initiated with a Buy at Loop Capital, while Alphabet (GOOG, GOOGL) was initiated with a Hold. 4. Pfizer (PFE) was resumed with an Overweight at Morgan Stanley. 5. Neon Therapeutics (NTGN) was initiated with a Buy at Mizuho. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

ARZGY

Generali

$0.00

(0.00%)

19:22
06/19/19
06/19
19:22
06/19/19
19:22
Downgrade
Generali rating change at JPMorgan »

Generali downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GO

Grocery Outlet

$0.00

(0.00%)

19:00
06/19/19
06/19
19:00
06/19/19
19:00
Syndicate
Grocery Outlet 17.19M share IPO priced at $22.00 »

The deal priced above the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 20

    Jun

WIX

Wix.com

$145.83

1.19 (0.82%)

18:57
06/19/19
06/19
18:57
06/19/19
18:57
Hot Stocks
Wix.com CEO: Q1 was very good for us »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AOBC

American Outdoor Brands

$9.17

0.13 (1.44%)

, ORCL

Oracle

$52.69

-0.19 (-0.36%)

18:44
06/19/19
06/19
18:44
06/19/19
18:44
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

AOBC

American Outdoor Brands

$9.17

0.13 (1.44%)

ORCL

Oracle

$52.69

-0.19 (-0.36%)

JSYN

Jensyn Acquisition

$5.00

-5.02 (-50.10%)

ABEO

Abeona Therapeutics

$4.90

-0.09 (-1.80%)

PIR

Pier 1 Imports

$0.67

-0.0059 (-0.87%)

SCS

Steelcase

$17.80

0.235 (1.34%)

LAND

Gladstone Land

$12.29

0.39 (3.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 19

    Jun

  • 19

    Jun

  • 20

    Jun

  • 24

    Jun

  • 26

    Jun

  • 26

    Jun

  • 10

    Jul

  • 20

    Jun

TMUS

T-Mobile

$78.28

1.79 (2.34%)

, S

Sprint

$7.46

0.24 (3.32%)

18:39
06/19/19
06/19
18:39
06/19/19
18:39
Periodicals
T-Mobile readies for Boost auction if Dish talks fall through, Reuters says »

T-Mobile (TMUS) is…

TMUS

T-Mobile

$78.28

1.79 (2.34%)

S

Sprint

$7.46

0.24 (3.32%)

DISH

Dish

$38.90

-0.18 (-0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBRA

Zebra Technologies

$200.57

-1.1 (-0.55%)

18:39
06/19/19
06/19
18:39
06/19/19
18:39
Hot Stocks
Zebra Technologies Chief of Product sells 5K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBRA

Zebra Technologies

$200.57

-1.1 (-0.55%)

18:23
06/19/19
06/19
18:23
06/19/19
18:23
Hot Stocks
Zebra Technologies CEO sells 20K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNH

UnitedHealth

$250.25

4.6 (1.87%)

, DVA

DaVita

$51.27

1.51 (3.03%)

18:13
06/19/19
06/19
18:13
06/19/19
18:13
Hot Stocks
FTC approves UnitedHealth's acquisition of DaVita Medical with conditions »

Healthcare provider and…

UNH

UnitedHealth

$250.25

4.6 (1.87%)

DVA

DaVita

$51.27

1.51 (3.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

SRRK

Scholar Rock

$17.11

-2.835 (-14.21%)

18:11
06/19/19
06/19
18:11
06/19/19
18:11
Syndicate
Scholar Rock 3M share Secondary priced at $15.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

QDEL

Quidel

$58.80

1.7 (2.98%)

18:01
06/19/19
06/19
18:01
06/19/19
18:01
Hot Stocks
Quidel receives 510k clearance for Triage TOX Drug Screen »

Quidel Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DELL

Dell Technologies

$53.39

1.88 (3.65%)

, HPQ

HP Inc.

$20.63

0.1 (0.49%)

17:59
06/19/19
06/19
17:59
06/19/19
17:59
Periodicals
Dell, HP, Intel, Microsoft express opposition to Trump tariffs, Bloomberg says »

Dell Technologies (DELL),…

DELL

Dell Technologies

$53.39

1.88 (3.65%)

HPQ

HP Inc.

$20.63

0.1 (0.49%)

INTC

Intel

$47.08

-0.29 (-0.61%)

MSFT

Microsoft

$135.63

0.43 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 23

    Jun

  • 28

    Jun

  • 01

    Jul

  • 02

    Jul

  • 03

    Jul

  • 04

    Jul

  • 09

    Jul

  • 09

    Jul

  • 10

    Jul

  • 25

    Jul

  • 06

    Aug

ORCL

Oracle

$52.69

-0.19 (-0.36%)

17:54
06/19/19
06/19
17:54
06/19/19
17:54
Hot Stocks
Oracle says 20% of Autonomous Database customers new to company »

Says plans to launch free…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

CB

Chubb

$149.48

1.37 (0.92%)

17:54
06/19/19
06/19
17:54
06/19/19
17:54
Hot Stocks
Chubb CEO sells 215.6K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

CABO

Cable One

$1,166.79

15.59 (1.35%)

17:52
06/19/19
06/19
17:52
06/19/19
17:52
Hot Stocks
Cable One COO sells 535 shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WORK

Slack Technologies

$0.00

(0.00%)

17:50
06/19/19
06/19
17:50
06/19/19
17:50
Syndicate
Slack Technologies stock reference point set at $26 per share »

Slack Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AABA

Altaba

$68.40

-0.24 (-0.35%)

17:37
06/19/19
06/19
17:37
06/19/19
17:37
Hot Stocks
Farallon Capital takes 5.0% passive stake in Altaba »

Farallon Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

MSFT

Microsoft

$135.63

0.43 (0.32%)

17:36
06/19/19
06/19
17:36
06/19/19
17:36
Hot Stocks
Microsoft's online gaming service Xbox Live having issues with core services »

Xbox Live said, Xbox Live…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 23

    Jun

  • 09

    Jul

  • 10

    Jul

  • 06

    Aug

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$293.02

0.69 (0.24%)

17:33
06/19/19
06/19
17:33
06/19/19
17:33
Periodicals
Mexico votes to ratify trade deal with U.S., Canada, WSJ reports »

Mexico's Senate has…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$293.02

0.69 (0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GVA

Granite Construction

$44.83

0.19 (0.43%)

17:31
06/19/19
06/19
17:31
06/19/19
17:31
Hot Stocks
Granite Construction awarded $39M dam project in Texas »

Granite announced that is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CGC

Canopy Growth

$42.78

0.695 (1.65%)

17:25
06/19/19
06/19
17:25
06/19/19
17:25
Hot Stocks
Canopy Growth shareholders approve resolutions regarding Acreage acquisition »

Canopy Growth's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 21

    Jun

VTR

Ventas

$69.65

1.05 (1.53%)

17:21
06/19/19
06/19
17:21
06/19/19
17:21
Recommendations
Ventas analyst commentary at MUFG »

Ventas price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$187.41

-1.05 (-0.56%)

17:20
06/19/19
06/19
17:20
06/19/19
17:20
Periodicals
Facebook's crypto plans to face U.S. Senate scrutiny, Reuters reports »

According to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 10

    Jul

ORCL

Oracle

$52.69

-0.19 (-0.36%)

17:14
06/19/19
06/19
17:14
06/19/19
17:14
Hot Stocks
Breaking Hot Stocks news story on Oracle »

Oracle sees 1% revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

ORCL

Oracle

$52.69

-0.19 (-0.36%)

17:13
06/19/19
06/19
17:13
06/19/19
17:13
Hot Stocks
Breaking Hot Stocks news story on Oracle »

Oracle sees FY20 CapEx…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

ORCL

Oracle

$52.69

-0.19 (-0.36%)

17:12
06/19/19
06/19
17:12
06/19/19
17:12
Earnings
Oracle sees Q1 adjusted EPS 80c-82c, consensus 80c »

Sees Q1 revenue growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.